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ORIGINAL INVESTIGATION
Alterations in lipid transfers to HDL 
associated with the presence of coronary artery 
disease in patients with type 2 diabetes mellitus
Marilia C O Sprandel1, Whady A Hueb2, Alexandre Segre2, José A F Ramires2, Roberto Kalil‑Filho2 
and Raul C Maranhão1,3*
Abstract 
Background: We previously showed that unesterified‑cholesterol transfer to high‑density lipoprotein (HDL), a crucial 
step in cholesterol esterification and role in reverse cholesterol transport, was diminished in non‑diabetic patients 
with coronary artery disease (CAD). The aim was to investigate whether, in patients with type 2 diabetes mellitus 
(T2DM), the occurrence of CAD was also associated with alterations in lipid transfers and other parameters of plasma 
lipid metabolism.
Methods: Seventy‑nine T2DM with CAD and 76 T2DM without CAD, confirmed by cineangiography, paired for sex, 
age (40–80 years), BMI and without statin use, were studied. In vitro transfer of four lipids to HDL was performed by 
incubating plasma of each patient with a donor emulsion containing radioactive lipids during 1 h at 37 °C. Lipids 
transferred to HDL were measured after chemical precipitation of non‑HDL fractions and the emulsion. Results are 
expressed as % of total radioactivity of each lipid in HDL.
Results: In T2DM + CAD, LDL‑cholesterol and apo B were higher than in T2DM. T2DM + CAD also showed dimin‑
ished transfer to HDL of unesterified cholesterol (T2DM + CAD = 7.6 ± 1.2; T2DM = 8.2 ± 1.5 %, p < 0.01) and of 
cholesteryl‑esters (4.0 ± 0.6 vs 4.3 ± 0.7, p < 0.01). Unesterified cholesterol in the non‑HDL serum fraction was higher 
in T2DM + CAD (0.93 ± 0.20 vs 0.85 ± 0.15, p = 0.02) and CETP concentration was diminished (2.1 ± 1.0 vs 2.5 ± 1.1, 
p = 0.02). Lecithin‑cholesterol acyltransferase activity, HDL size and lipid composition were equal.
Conclusion: Reduction in T2DM + CAD of cholesterol transfer to HDL may impair cholesterol esterification and 
reverse cholesterol transport and altogether with simultaneous increased plasma unesterified cholesterol may facili‑
tate CAD development in T2DM.
Keywords: Coronary artery disease, Type 2 diabetes, Lipid transfers, High‑density lipoprotein, HDL, Nanoparticles, 
Cholesterol
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Background
The most frequent fatal complication of type 2 diabe-
tes mellitus (T2DM) is coronary artery disease (CAD), 
accounting for nearly 60  % of deaths among T2DM 
patients. Patients with T2DM are exposed to a two-four 
fold higher risk of developing CAD than the general 
population [1]. Thus, it is of fundamental importance in 
T2DM management to determine the factors that predis-
pose these patients to develop CAD. Several steps in the 
metabolism of the plasma lipoproteins are regulated by 
insulin [2] and in T2DM the appearance of dyslipidemia, 
characterized by hypertriglyceridemia and low high-den-
sity lipoprotein (HDL) cholesterol are frequent and may 
increase CAD risk [3–5].
In respect to HDL, the negative correlation between 
HDL-cholesterol and the incidence of CAD was well 
established in several epidemiologic studies [6–8]. 
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However, it has been perceived that this lipoprotein, that 
has several protective anti-atherogenic functions, should 
not be evaluated only by HDL-cholesterol concentration 
but also by methods testing the functional aspects.
In the bloodstream, HDL is constantly being remod-
eled and transfer of lipids from other lipoproteins and 
from the peripheral cells to HDL and from HDL to other 
lipoprotein classes is crucial in the HDL metabolism. Nas-
cent HDL is produced in the liver and intestine as discoid 
particles composed of apolipoprotein (apo) A-I, phos-
pholipids and unesterified cholesterol [9]. These parti-
cles are progressively transformed into a spherical shape 
by the transfer of lipids to HDL and cholesterol esterifi-
cation. HDL is thus continuously being remodeled, and 
lipid transfers to and from the lipoprotein are an essential 
part of HDL metabolism and atheroprotective functions 
[10]. Transfer of lipids is facilitated by transfer proteins 
such as cholesteryl ester transfer protein (CETP) and 
phospholipid transfer protein (PLTP) that are involved in 
the transfers of core (cholesteryl esters and triglycerides) 
and surface (phospholipids and unesterified cholesterol) 
lipids, respectively [11]. The role of CETP and PLTP in 
atherogenesis and T2DM is still not completely under-
stood [12, 13], but the HDL status is clearly more affected 
by lipid transfers than VLDL and LDL. Impairment of 
lipid transfers by CETP inhibitors leads to pronounced 
HDL increases, with lesser effects on the other lipopro-
tein classes [14]. CETP inhibition aiming to increase HDL 
cholesterol levels has become a novel target in anti-ath-
erogenic therapeutics [14], and this highlights the impor-
tance to investigate transfer of lipids involving HDL.
Cholesterol esterification, a reaction that is catalyzed 
by lecithin-cholesterol acyltransferase (LCAT), using apo 
A-I as a co-factor [9], is essential for stabilization of the 
cholesterol plasma pool and occurs mainly in the HDL 
fraction that contains both LCAT and apo A-I. In the 
reverse cholesterol transport process, HDL shuttles cho-
lesterol from peripheral tissues to the liver for excretion 
in the bile. This process is not affected by the increased 
serum levels of advanced glycation end-products (AGE) 
occurring in T2DM [15]. HDL has also anti-inflamma-
tory, anti-oxidant, anti-coagulant and anti-apoptotic 
properties, all presumably protective against CAD [9].
Recently, we described an in  vitro assay to assess the 
simultaneous transfer to HDL of the four main lipids, 
unesterified cholesterol, cholesteryl esters, phospho-
lipids, and triglycerides, from a donor lipid nanoemul-
sion to HDL [16, 17]. We subsequently reported that the 
lipid transfers were disturbed in patients with premature 
CAD. In those patients, among other changes in lipid 
transfers, the transfer of unesterified cholesterol to the 
HDL fraction was diminished, independent of the HDL-
cholesterol levels [18].
It is fundamental to explore the features of T2DM 
patients with concomitant CAD that distinguishes this 
population from T2DM patients that did not develop the 
disease. Understanding of those features may improve 
the prevention of the macrovascular complications. Thus, 
the aim of this study was to investigate whether develop-
ment of CAD in T2DM patients is associated with altera-
tions in lipid transfers to HDL, as compared with T2DM 
patients without CAD. Factors related with this process, 
such as HDL lipid composition, plasma CETP, LCAT 
and unesterified cholesterol were also studied in the two 
groups.
Methods
Study subjects
For this case–control study, patients with T2DM were 
selected from the Outpatient Clinic of the Heart Insti-
tute at the University of São Paulo Medical School. All 
participated of the MASS study group [19]. Patients that 
were using statins or other lipid-lowering drugs discon-
tinued this treatment for at least 45  days before they 
participated in this study. Seventy-nine patients had 
cardiovascular disease confirmed by coronary cineangi-
ography showing lesions with >50  % luminal reduction 
(T2DM +  CAD), whereas 76 patients had angiographi-
cally normal arteries (T2DM). Exclusion criteria were 
severe hypertension (based on the Joint National Com-
mittee VI criteria for blood pressure >180/110  mmHg), 
renal failure (when plasma creatinine levels were above 
the reference threshold), hepatic impairment (if activity 
of aspartate aminotransferase, alanine aminotransferase, 
gamma-glutamyltransferase, and alkaline phosphatase 
were above the reference thresholds), hypothyroidism 
and recent surgery. The two groups were paired for sex, 
age, and BMI.
The study conformed to the guidelines set out in the 
Declaration of Helsinki and was approved by the Eth-
ics Committee of the University of São Paulo Medical 
School. All participants gave written informed consent 
for participation in the study.
Laboratory analysis
Plasma total cholesterol (CHOD-PAP; Roche, Basel, 
Swiss) and triglycerides (Triglyceride Rapid; Roche) were 
determined by using commercial kits (Labtest, Minas 
Gerais, Brazil) from plasma samples collected after a 12-h 
fast. HDL-cholesterol was measured by the same method 
used for total cholesterol after lipoprotein precipitation 
with magnesium phosphotungstate. LDL-cholesterol was 
estimated by the Friedewald formula [20]. The non-HDL 
cholesterol level was calculated by subtracting the HDL 
from the total cholesterol concentration. Unesterified 
cholesterol and non-esterified fatty acids (NEFA) were 
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also determined by an enzymatic colorimetric method 
(Wako, Richmond, VA, USA). Serum concentrations of 
apo A-I and apo B were determined by the immunoturbi-
dimetric method (Roche, Mannhein, Germany).
HDL particle size determination
The diameter of the HDL fraction particles was measured 
in fresh plasma collected after a 12-h fast as described 
previously [21], using a ZetaPALS Zeta Potential Ana-
lyzer (Brookhaven, Holtsville, NY, USA).
Lipid composition of the HDL fraction
The HDL fraction was obtained from the whole plasma 
after precipitation of the apo B-containing lipoproteins 
with magnesium phosphotungstate. Triglyceride con-
centration in the HDL fraction was determined using a 
commercial kit (Labtest, Minas Gerais, Brazil). Unest-
erified cholesterol and phospholipid concentrations were 
determined by using an enzyme-linked immunosorbent 
assay (Wako, Richmond, VA, USA). Esterified choles-
terol in the HDL fraction was calculated as the difference 
between total and unesterified cholesterol of the HDL 
multiplied by 1.67 to adjust for M.W. of esterified choles-
terol [22].
Nanoemulsion preparation
The lipid donor nanoemulsion was prepared from a lipid 
mixture composed of 40  mg cholesteryl oleate, 20  mg 
egg phosphatidylcholine, 1 mg triolein, and 0.5 mg cho-
lesterol purchased from Sigma Chemical Company (St. 
Louis, MO, USA). Emulsification of lipids by prolonged 
ultrasonic irradiation in aqueous media and the proce-
dure of two-step ultracentrifugation of the crude emul-
sion with density adjustment by addition of KBr to 
obtain the nanoemulsion was carried out by the method 
described previously [16]. The nanoemulsion fraction 
was dialyzed against 0.9 % NaCl solution. Trace amounts 
of cholesteryl [-14C] oleate and glycerol tri [9, 10(n)-3H] 
oleate or [7(n)-3H] cholesterol and l-3-phosphatidyl-
choline, 1-stearoyl-2-[1-14C] arachidonyl (Perkin Elmer, 
Waltham, MA, USA) were added to the initial solution.
Lipid transfer from the donor lipid nanoemulsion to HDL
The in  vitro assay of lipid transfer from the nanoemul-
sion to HDL was previously described by Lo Prete et al. 
[16]. In brief, it consisted of the incubation of the nanoe-
mulsion labeled with 3H-Cholesteryl ester and 14C-Phos-
pholipid or with 14C-Unesterified cholesterol and 
3H-Triglyceride with whole plasma followed by chemical 
precipitation of the apo B containing lipoproteins and 
the nanoemulsion. After the chemical precipitation of 
the nanoemulsion and the apo B lipoprotein fraction, the 
supernatant containing the HDL fraction radioactivity 
was measured in a scintillation solution. The results of 
radioactive transfer from the nanoemulsion to HDL were 
expressed as percentage of the total incubated radioactiv-
ity found in the HDL-containing supernatant.
Determination of CETP concentration and LCAT activity
Serum CETP activity was measured using commercially 
available CETP activity assay kit (BioVision, Mountain 
View, CA, USA). Serum CETP concentration was deter-
mined by the immunoassay method  (ALPCO Diagnostics, 
Salem, NH, USA) and plasma LCAT activity was  deter-
mined by fluorometric assay kit (Calbiochem, Germany). 
This assay is based on the hydrolysis of an artificial LCAT 
substrate that fluoresces at 470 nm, resulting in a product 
that fluoresces at 390 nm. LCAT activity is defined as the 
change in the ratio of 390/470 nm fluorescence emission 
intensities.
Statistical analysis
The results are expressed as mean ± SD. Data were com-
pared using the unpaired Student t test. The Fisher’s 
exact test was used to analyze percentages. Pearson’s 
test was used for correlation analyses. In all analyses, 
parameters were considered significantly different when 
p < 0.05. Multiple linear regression analysis was used to 
determine the independent contribution of variables to 
lipid transfers. The model was based on variables that 
had significant association with lipid transfers on univari-
ate analyses, besides age, sex, BMI and CAD presence. 
Statistical analyses were performed using SPSS 20.0 for 
Windows (SPSS, Chicago, IL, USA).
Results
Table 1 shows the physical and clinical data of the study 
subjects. The two groups were different only in time 
elapsed after diabetes diagnosis, but were equal regarding 
age, BMI, waist circumference, and percentage of subjects 
with arterial hypertension. T2DM and T2DM  +  CAD 
groups were also equal regarding percentage taking insu-
lin and the diabetes control parameters fasting glucose 
and HbA1c.
Serum biochemical parameters of the two groups are 
shown in Table  2. Regarding the two main parameters 
involved in diabetes dyslipidemia, namely triglycerides 
and HDL-cholesterol were not different in the two groups. 
In contrast, LDL (p  <  0.0001) and non-HDL-cholesterol 
(p = 0.01) were higher in the T2DM + CAD than in the 
T2DM group. Serum unesterified cholesterol levels were 
also higher in T2DM + CAD than in T2DM (p =  0.02). 
Regarding the serum concentrations of the apos, apo B 
was higher in T2DM + CAD (p = 0.03), whereas apo A-I 
did not differ between the two groups. The triglycerides/
HDL cholesterol and LDL cholesterol/apo B ratios were 
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not different between the two groups. Table 3 shows the 
transfer of the four lipids from the donor nanoemulsion 
to the HDL plasma fraction. The transfers of unesterified 
cholesterol and of cholesteryl ester were diminished in the 
T2DM  +  CAD patients compared to the T2DM group 
(p  <  0.01), but the phospholipid and triglyceride transfer 
rates were similar. Also shown in Table 3, when comparing 
the two groups, the lipid composition of the HDL fraction 
and the HDL size were not different. 
The concentration of CETP in the serum was lower in 
T2DM  +  CAD than in T2DM patients (p  =  0.02), but 
CETP activity was not different between groups. The 
activity of the cholesterol esterification enzyme LCAT 
was also similar in the two groups (Table 2).
Table 4 shows the results of the correlation study per-
formed by univariate analysis in the two groups studied 
(T2DM and T2DM + CAD). Values of the transfer of the 
four lipids, CETP serum concentration, LCAT activity 
and serum concentration of unesterified cholesterol were 
plotted against the several parameters measured here. 
Significant positive correlations were found between 
transfers of all four lipids and HDL-cholesterol and apo 
A-I, whereas negative correlations were found between 
the transfers of the four lipids and LCAT activity.
The unesterified cholesterol transfer to HDL positively 
correlated with the serum concentration of triglycerides 
and with the percentage of unesterified cholesterol in 
the composition of the HDL fraction. Unesterified cho-
lesterol transfer to HDL correlated negatively with apo B, 
serum concentration of unesterified cholesterol and with 
the ratio triglycerides/HDL-cholesterol and positively 
with CETP concentration. The cholesteryl ester transfer 
to HDL was positively correlated with LDL-cholesterol, 
triglyceride content in HDL and CETP concentration. 
Table 1 Clinical and  physical characteristics of  T2DM 
patients with or without CAD
Data are expressed as mean ± SD.
NS nonstatistically significant, M Male, F Female, BMI body mass index, HbA1c 
glycated hemoglobin, ACEi angiotensin converting enzyme inhibitor.
Parameters T2DM T2DM + CAD P value
Number of patients 
(M/F)
75 (33/42) 79 (42/37) NS
Age (years) 63 ± 9 63 ± 8 NS
BMI (kg/m2) 31.4 ± 6.1 30.8 ± 6.0 NS
Waist circumference 
(cm)
107 ± 16 104 ± 13 NS
Time from T2DM  
diagnosis (years)
7 ± 6 10 ± 9 0.01
Arterial hypertension 
(%)
93 89 NS
Fasting glucose 
(mmol/L)
7.3 ± 1.8 7.0 ± 2.4 NS
HbA1c % (mmol/L) 7.2 ± 1.6 (55 ± 17) 7.1 ± 1.8 (54 ± 19) NS
Current medications (%)
 Insulin 25 29 NS
 Metformin 67 84 0.02
 Sulfonylurea 29 25 NS
 ACEi 58 43 NS
 Beta‑blocker 63 76 NS
Table 2 Serum biochemistry data of  T2DM patients 
with or without CAD
Data are expressed as mean ± SD.
NS nonstatistically significant, HDL high density lipoprotein, LDL low density 
lipoprotein, NEFA non-esterified fatty acids, CETP cholesteryl ester transfer 
protein, LCAT lecithin-cholesterol acyltransferase, LCAT activity is expressed by 
the hydrolyzed monomer ratio 390/470 nm.
Parameters T2DM T2DM + CAD P value
Triglycerides (mmol/L) 1.72 ± 0.78 1.91 ± 0.81 NS
Cholesterol (mmol/L)
 Total 4.99 ± 0.93 5.63 ± 1.24 <0.001
 LDL 3.20 ± 0.85 3.80 ± 1.13 <0.001
 HDL 1.06 ± 0.23 0.98 ± 0.20 NS
 Non‑HDL 3.90 ± 0.95 4.65 ± 1.18 0.01
 Unesterified cholesterol 0.85 ± 0.15 0.93 ± 0.20 0.02
Triglycerides/HDL‑cholesterol 8.5 ± 5.1 10.4 ± 7.3 NS
Apolipoproteins (mg/dL)
 A‑I 139.3 ± 28.1 132.5 ± 24.3 NS
 B 96.0 ± 19.5 103.1 ± 20.4 0.03
LDL cholesterol/apo B 1.34 ± 0.29 1.23 ± 0.57 NS
NEFA (g/L) 0.13 ± 0.06 0.11 ± 0.05 NS
Total/unesterified cholesterol 5.8 ± 1.0 6.2 ± 1.2 0.05
CETP (µg/mL) 2.5 ± 1.1 2.1 ± 1.0 0.02
CETP activity (pmol/µL/h) 68.4 ± 15.6 70.4 ± 12.5 NS
LCAT activity 1.33 ± 0.10 1.34 ± 0.12 NS
Table 3 In vitro lipid transfers to  HDL and  HDL composi-
tion in T2DM patients with or without CAD
Data are expressed as mean ± SD.
NS nonstatistically significant, HDL high density lipoprotein.
Parameters T2DM T2DM + CAD P value
Lipid transfers (%)
 Unesterified cholesterol 8.2 ± 1.5 7.6 ± 1.2 0.007
 Esterified Cholesterol 4.3 ± 0.7 4.0 ± 0.6 0.005
 Phospholipids 25.5 ± 2.6 25.9 ± 2.1 NS
 Triglycerides 5.0 ± 0.7 4.9 ± 0.8 NS
Lipid composition of HDL (%)
 Unesterified cholesterol 6.0 ± 1.7 5.6 ± 1.6 NS
 Esterified cholesterol 34.7 ± 5.6 34.0 ± 5.5 NS
 Phospholipids 50.3 ± 6.1 52.0 ± 6.0 NS
 Triglycerides 8.9 ± 2.5 8.4 ± 2.6 NS
HDL diameter (nm) 9.0 ± 0.6 8.9 ± 1.2 NS
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The phospholipid transfer to HDL correlated positively 
with LDL-cholesterol. The triglyceride transfer to HDL 
correlated positively with LDL-cholesterol and non HDL-
cholesterol concentrations. The triglyceride transfer also 
positively correlated with the percentage of unesterified 
and the percentage of esterified cholesterol in the compo-
sition of the HDL fraction and with the serum concentra-
tion of CETP. All the transfer rates positively correlated 
with each other, except the transfers of cholesteryl ester 
and phospholipids.
The serum concentration of unesterified cholesterol 
correlated positively with serum concentration of LDL-
cholesterol, triglycerides, non-HDL-cholesterol and apo 
B. The serum concentration of unesterified cholesterol 
negatively correlated with the percentage of unesterified 
cholesterol in the composition of the HDL fraction.
Cholesteryl ester transfer protein concentration in 
the serum correlated positively with the concentrations 
of triglycerides and of apo A-I, as well as with the per-
centage of triglycerides and the percentage of unesteri-
fied cholesterol in the composition of the HDL fraction. 
LCAT activity positively correlated with serum concen-
tration of NEFA and negatively with the concentration of 
HDL-cholesterol and of apo A-I.
By multiple linear regression analysis, unesterified 
cholesterol transfer was independently associated with 
Table 4 Correlations between  lipid transfers to  HDL, serum concentrations of  CETP, unesterified cholesterol and  LCAT 
activity
BMI Body mass index, HDL high density lipoprotein, LDL low density lipoprotein, TG triglycerides, UC unesterified cholesterol, HbA1c glycated hemoglobin, Apo 
apolipoprotein, CETP cholesteryl ester transfer protein, LCAT lecithin-cholesterol acyltransferase, NEFA non-esterified fatty acids.
* p value <0.05.
† p value <0.01.
Parameters Lipid transfers Unesterified  
cholesterol
LCAT  
activity
CETP  
concentration
Unesterified  
cholesterol
Cholesteryl  
ester
Phospholipid Triglyceride
HDL‑cholesterol 0.633† 0.333† 0.269† 0.383† −0.088 −0.313† 0.168
LDL‑cholesterol −0.005 0.218* 0.220† 0.182* 0.416† −0.170 0.059
Tryglicerides −0.229† 0.103 −0.144 0.030 0.381† 0.034 −0.012
non HDL‑cholesterol −0.078 0.212* 0.188* 0.180* 0.511† −0.120 0.050
TG/HDL‑cholesterol −0.322† 0.046 −0.059 −0.044 0.403† 0.083 −0.020
Unesterified choles‑
terol
−0.255† 0.119 0.007 0.040 – −0.044 0.058
Total/unesterified 
cholesterol
0.226† 0.128 0.253† 0.154 −0.402† −0.059 0.033
NEFA 0.490 0.044 −0.158 −0.054 0.003 0.265† −0.056
Fasting glucose −0.154 0.081 −0.098 −0.108 0.148 0.100 0.018
HbA1c −0.022 0.027 −0.054 0.044 0.166* −0.037 0.068
Apo A‑I 0.697† 0.584† 0.316† 0.334† −0.039 −0.383† 0.305†
Apo B −0.219† 0.091 0.109 0.096 0.617† −0.141 0.096
CETP concentration 0.185* 0.522† 0.117 0.183* 0.058 −0.149 0.032
LCAT activity −0.460† −0.235† −0.317† −0.283† −0.044 – −0.056
Cholesteryl ester 
transfer
0.364† – 0.048 0.224† 0.119 −0.235† 0.522†
Phospholipid 
transfer
0.568† 0.048 – 0.576† 0.007 −0.317† 0.117
Unesterified choles‑
terol transfer
– 0.364† 0.568† 0.561† −0.255† −0.460† 0.185*
Triglyceride transfer 0.561† 0.224† 0.576† – 0.040 −0.283† 0.183*
HDL diameter 0.055 0.122 −0.099 −0.006 −0.150 0.037 0.100
HDL lipid composition
 Unesterified cho‑
lesterol
0.321† 0.121 0.057 0.204* −0.218* −0.111 0.181*
 Tryglicerides −0.134 0.185* −0.151 −0.193* −0.004 0.135 0.196*
 Phospholipids −0.161 −0.035 −0.036 −0.129 0.123 0.037 −0.176
 Cholesteryl ester 0.141 −0.084 0.091 0.170 −0.066 −0.066 0.049
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the presence of CAD (β  =  −0.416, p  =  0.003), LCAT 
activity (β  =  −3.184, p  <  0.001), apo A-I (β  =  −0.037, 
p < 0.001), apo B (β = −0.017, p < 0.001), fasting glycemia 
(β = −0.005, p = 0.003), and sex (β = −0.365, p = 0.021).
Cholesteryl ester transfer to HDL was independently 
associated with the presence of CAD (β  =  −0.211, 
p =  0.031), CETP concentration (β =  0.241, p < 0.001), 
HDL-cholesterol (β = −0.02, p = 0.009), LDL-cholesterol 
(β = 0.003, p = 0.024), and apo A-I (β = 0.017, p < 0.001).
Phospholipid transfer to HDL was independently associ-
ated with LDL-cholesterol (β = 0.009, p < 0.001), apo A-I 
(β = 0.022, p ≤ 0.001), age (β = −0.026, p = 0.003), sex 
(β = −0.403, p = 0.023), but not with CAD (p = 0.796).
Triglyceride transfer to HDL was independently asso-
ciated with LCAT (β  =  −1.2, p  =  0.05) and apo A-I 
(β = 0.009, p = 0.001), but not with CAD (β = −0.139, 
p = 0.273).
T2DM + CAD had total and LDL cholesterol and apo 
B concentrations greater than in T2DM, which could 
influence the results of lipid transfers. To address this 
issue, an analysis was made by pairing the groups accord-
ing to their values of total, LDL and HDL cholesterol and 
apo B. In this analysis, T2DM + CAD had 64 and T2DM 
had 65 participants. After this pairing, the outcome of 
the results remained the same, i.e., compared to T2DM, 
T2DM  +  CAD had diminished transfer of unesterified 
(7.6 ±  1.2 vs 8.2 ±  1.5  %, p =  0.01) and esterified cho-
lesterol (3.9 ± 0.6 vs 4.3 ± 0.7 %, p < 0.01) whereas tri-
glyceride (4.9 ± 0.8 vs 5.0 ± 0.8 %, NS) and phospholipid 
(25.9 ± 2.1 vs 25.7 ± 2.6 %, NS) transfers were equal.
Discussion
The results of this study, in which all participants had the 
presence or absence of CAD confirmed by coronary cine-
angiography, indicate that the plasma lipid atherogenic 
alterations classically associated with T2DM, i.e., low 
HDL-cholesterol and hypertriglyceridemia, did not dis-
criminate between T2DM and T2DM  +  CAD patients. 
The triglycerides/HDL-cholesterol ratio which is also 
related with insulin resistance and atherogenesis [23, 
24] was also not discriminative between the T2DM and 
T2DM  +  CAD groups. Rather, higher LDL-cholesterol, 
non-HDL-cholesterol and apo B were the lipid mark-
ers for T2DM + CAD. The ratio LDL-cholesterol/apo B, 
which is a surrogate for the more atherogenic small dense 
LDL sub-fraction, and is altered in T2DM was not differ-
ent between the two groups.
Data in the literature comparing the plasma lipid pro-
file of T2DM patients with and without CAD are scarce. 
In this respect, similar to our findings, Seviour et al. [25] 
reported that LDL-cholesterol and apo B concentrations 
were higher in T2DM with CAD than in T2DM patients 
without CAD, without differences in HDL-cholesterol 
or triglyceride values. In the study by Kahri et al. [26], all 
three plasma lipid parameters, LDL and HDL-cholesterol 
and triglycerides, were equal in T2DM with or without 
CAD. Thus, the two previous and the current study con-
verge in the finding that low HDL-cholesterol and high 
triglycerides, were not differentiating factors between 
CAD and non-CAD T2DM patients. Likewise, NEFA, 
which is characteristically elevated in T2DM resulting 
from the mobilization of fatty acids in insulin action defi-
ciency, were not different between the two groups. This 
is a first-time observation to our knowledge, NEFA was 
not examined as a CAD risk factor in T2DM patients in 
either transversal, as the current study, or in prospective 
studies from the literature.
The main novel finding in this study was the diminished 
transfer of unesterified cholesterol to the HDL fraction in 
T2DM + CAD, despite the fact that the HDL-cholesterol 
and apo A-I concentrations were equal in both groups. 
Diminished transfer of unesterified cholesterol was 
also found in patients with precocious (<50 years) CAD 
without T2DM in comparison with non-CAD control 
subjects. In that study, all analyzed traditional lipid risk 
factors such as LDL and HDL-cholesterol and triglycer-
ides were equal in CAD and non-CAD subjects [18].
In T2DM  +  CAD unesterified cholesterol concen-
tration in total and in non-HDL plasma fraction was 
higher than in T2DM. In contrast, in the HDL plasma 
fraction the unesterified cholesterol concentration was 
equal in the two groups. The association of higher unes-
terified cholesterol serum concentration with CAD with-
out T2DM was reported by Frohlich and Dobiasova in 
women [27], but our current results in T2DM + CAD are 
a novel finding.
In the correlation study, we found that the unesterified 
cholesterol serum concentration correlates negatively 
with unesterified cholesterol transfer to HDL and unest-
erified cholesterol in HDL composition. The suggestion is 
then left that because less unesterified cholesterol enters 
in the HDL wherein it is esterified, more remains in the 
non-HDL fraction.
The activity of LCAT, the enzyme that catalyzes choles-
terol esterification in the plasma, did not differ between 
T2DM + CAD and T2DM, but was negatively correlated 
with all lipid transfers. The status of LCAT activity is a 
controversial issue in atherosclerosis [28–30] and has not 
yet been investigated in T2DM with CAD. On the other 
hand, the fact that esterified cholesterol transfer was 
negatively correlated with LCAT activity suggests that 
higher rates of cholesterol esterification tend to stabilize 
the HDL fraction, so that the entry of all lipids into the 
lipoprotein particles is inhibited.
Esterification stabilizes the cholesterol pool because 
newly esterified cholesterol is sequestered into the 
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lipoprotein core. Unesterified cholesterol at the lipopro-
tein surface can conceivably diffuse into the surrounding 
aqueous medium and eventually precipitate in the artery. 
In contrast, cholesteryl esters at the lipoprotein core are 
translocated from the lipoprotein only by a CETP-medi-
ated process [31]. In addition, cholesterol esterification is 
also a driving force for the reverse transport, since it cre-
ates the gradient for the surface of the HDL particles to 
receive additional unesterified cholesterol from the cells. 
Diminution of unesterified cholesterol transfer to HDL 
can then diminish the esterification process by dimin-
ishing the substrate offer, and impairing the cholesterol 
reverse transport.
In a previous study, we injected lipidic nanoemulsions 
with labeled unesterified cholesterol and cholesteryl ester 
in CAD and control non-CAD subjects, all with presence 
or absence of CAD documented by coronary cineangiog-
raphy: the removal of unesterified cholesterol from the 
plasma was faster than that of cholesteryl ester in CAD, 
indicating that in CAD patients unesterified cholesterol 
was being dissociated from the nanoparticles [32]. The 
possibility was raised that unesterified cholesterol dis-
sociated from the particles could be deposited in the 
arterial wall, as suggested by analyzing vessel fragments 
of patients who underwent revascularization previously 
injected with the labeled nanoemulsion [31].
Thus, in CAD patients, regardless of their having 
T2DM or not, the suggestion is left from the lipid trans-
fer assay results and unesterified cholesterol serum 
concentration that the presence of CAD is associated 
with dynamic aspects of unesterified cholesterol intra-
vascular metabolism. It would be tempting to examine 
whether the transfer of unesterified cholesterol from 
cultivated murine macrophages to HDL would also be 
decreased in T2DM +  CAD, as Khera et  al. showed in 
non-diabetic CAD patients [33]. Similarly to our previ-
ous study in non-diabetic CAD patients, our results of 
diminished transfer of unesterified cholesterol to HDL in 
T2DM +  CAD also point to a second defective step in 
unesterified cholesterol metabolism, now involving the 
entry of unesterified cholesterol from lipoproteins in the 
HDL fraction. Indeed, the ability of HDL to accept unes-
terified cholesterol is essential for cholesterol esterifica-
tion and drives reverse cholesterol transport.
Another outcome of the lipid transfer study was the 
decrease in the transfer of cholesteryl ester to HDL in 
T2DM + CAD. Since CETP facilitates cholesteryl ester 
transfers, this was probably related to the diminution of 
the concentration of CETP observed in T2DM + CAD. 
In T2DM, CETP concentration was reportedly high in 
two studies [34, 35] and low in one [36]. The current 
study is the first to compare T2DM patients without and 
with CAD. In this context, it could be postulated that 
high CETP concentration, together with high choles-
teryl ester transfer to HDL is protective against CAD in 
T2DM patients. Phospholipid and triglyceride transfers 
were not altered in T2DM + CAD relative to T2DM. In 
respect to triglycerides, since CETP concentration was 
decreased in T2DM +  CAD it would be expected that 
the triglyceride entry would also be decreased, since tri-
glyceride transfers are also mediated by CETP and, as 
expected, in our correlation study, decreased CETP con-
centration corresponded to decreased triglyceride trans-
fer to HDL.
Cholesteryl ester transfer protein also positively cor-
related with the triglyceride content in HDL composi-
tion. This is quite expected because the net result of 
CETP action is enrichment of the HDL fraction with 
triglycerides.
It is worthwhile to point out that many factors present 
in the plasma that are difficult to account for can inter-
fere in the lipid transfers to HDL. In this respect, Mor-
ton et  al. [37] reported that the unesterified cholesterol 
content of the donor lipoproteins could modulate choles-
teryl ester transfer without changing triglyceride transfer. 
Since the unesterified cholesterol pool in the non-HDL is 
increased in T2DM + CAD, it is possible that the donor 
nanoemulsion becomes unesterified cholesterol-enriched 
in the plasma of those patients, which would contribute 
for the results of T2DM + CAD vs T2DM.
The lipid composition of the HDL fraction did not dif-
fer between T2DM + CAD and T2DM, which is some-
what unexpected in view of the decreased transfers to 
HDL of both unesterified cholesterol and cholesteryl 
ester. However, lipid transfers are bidirectional and the 
transfer assay used here measures only the entry of lipids 
into the HDL fraction and not the lipid exit. Thus, the 
fact that the unesterified cholesterol or the cholesteryl 
ester transfers were diminished does not necessarily 
imply a reduction of those lipids in HDL composition.
As limitations of the current study, some of the great 
number of variables that are present in T2DM, such as 
time from diabetes diagnosis, anti-glycemic and anti-
hypertensive medications, as well as lifestyle interven-
tions, were not equal in the two groups and may have 
eventually influenced the results.
An important finding of the correlation analysis was 
that the transfer of all four lipids positively correlated 
with the HDL-cholesterol and with the apo A-I con-
centration. This reflects the mass effect observed in the 
methodological study on lipid transfers [16], such that 
the greater the HDL concentration, expressed by the 
HDL-cholesterol and apo A-I concentrations, the higher 
the transfer of lipids to the HDL fraction.
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Conclusion
This study shows that although lower HDL-cholesterol 
was not a marker for the presence of CAD in patients 
with T2DM, the cholesterol transfers to the lipoprotein, 
both in the esterified and in the non-esterified forms, 
were indeed altered in T2DM + CAD patients as com-
pared to T2DM. Since HDL is the main cholesterol 
esterification site in the plasma compartment, decrease 
in the transfer of unesterified cholesterol to this lipopro-
tein fraction can interfere with the esterification pro-
cess, which is critical for the stabilization of the plasma 
cholesterol pool and the reverse cholesterol transport. 
In this regard, the unesterified cholesterol concentra-
tion in the plasma of the T2DM + CAD was higher than 
in T2DM, which is an atherogenic factor and can be 
accounted for the diminished transfer to HDL. In respect 
to the observed reduction in cholesteryl ester transfer to 
HDL in these patients, it was probably related with the 
lower CETP levels found in the T2DM +  CAD group. 
These results highlight the importance of the system-
atic dynamic studies of HDL metabolic and functional 
aspects beyond the simple determination of lipoprotein 
plasmatic concentration. As exemplified in this study, 
those novel parameters can unravel novel atherogenic 
mechanisms and therapeutic targets.
Abbreviations
CAD: coronary artery disease; T2DM: type 2 diabetes mellitus; LCAT: lecithin‑
cholesterol acyltransferase; APO: apolipoprotein; CETP: cholesteryl ester 
transfer protein; PLTP: phospholipid transfer protein; NEFA: non‑esterified fatty 
acids; AGE: advanced glycation end‑products.
Authors’ contributions
MCOS participated in the execution of the study, data collecting and analysis. 
WAH participated in the conception of the work and patient selection. AS 
participated in patient handling and selection and data collection. JAFR par‑
ticipated in the study conception and data interpretation. RKF participated in 
data interpretation and manuscript draft. RCM participated in the conception 
of the study, data interpretation and manuscript writing. All authors read and 
approved the final manuscript.
Author details
1 Lipid Metabolism Laboratory, Heart Institute, Medical School Hospital, 
University of São Paulo, São Paulo, Brazil. 2 Clinical Cardiology Division, Heart 
Institute, Medical School Hospital, University of São Paulo, São Paulo, Brazil. 
3 Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil. 
Acknowledgements
This study was supported by São Paulo State Research Support Foundation 
(Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP) São Paulo, 
Brazil. Dr. Maranhão and Dr Hueb have Research Awards from the National 
Council for Scientific and Technological Development (Conselho Nacional de 
Desenvolvimento Científico e Tecnológico, CNPq), Brasilia, Brazil.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 20 May 2015   Accepted: 1 August 2015
References
 1. Pasterkamp G (2013) Methods of accelerated atherosclerosis in diabetic 
patients. Heart 99:743–749
 2. Leança CC, Nunes VS, Panzoldo NB, Zago VS, Parra ES, Cazita PM et al 
(2013) Metabolism of plasma cholesterol and lipoprotein parameters are 
related to a higher degree of insulin sensitivity in high HDL‑C healthy 
normal weight subjects. Cardiovasc Diabetol 12:173
 3. Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin 
Pract Endocrinol Metab 5:150–159
 4. Fruchart JC, Davignon J, Hermans MP, Al‑Rubeaan K, Amarenco P, Ass‑
mann G et al (2014) Residual macrovascular risk in 2013: what have we 
learned? Cardiovasc Diabetol 13:26
 5. Yassine HN, Belopolskaya A, Schall C, Stump CS, Lau SS, Reaven PD (2014) 
Enhanced cholesterol efflux to HDL through the ABCA1 transporter in 
hypertriglyceridemia of type 2 diabetes. Metabolism 63:727–734
 6. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High 
density lipoprotein as a protective factor against coronary heart disease. 
The Framingham Study. Am J Med 62:707–714
 7. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke 
JD et al (1989) High‑density lipoprotein cholesterol and cardiovascular 
disease. Four prospective American studies. Circulation 79:8–15
 8. Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP et al 
(2013) Low Levels of high density lipoprotein cholesterol and increased 
risk of cardiovascular events in stable ischemic heart disease patients: a 
post hoc analysis from the COURAGE Trial. J Am Coll Cardiol 62:1826–1833
 9. Kontush A, Chapman MJ (2006) Functionally defective high‑density 
lipoprotein: a newtherapeutic target at the crossroads of dyslipidemia, 
inflammation, and atherosclerosis. Pharmacol Rev 58:342–374
 10. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein 
J et al (2012) Cholesterol efflux and atheroprotection: advancing the 
concept of reverse cholesterol transport. Circulation 125:1905–1919
 11. Tall A (1995) Plasma lipid transfer proteins. Ann Rev Biochem 64:235–257
 12. Siebel AL, Natoli AK, Yap FY, Carey AL, Reddy‑Luthmoodoo M, Sviridov D 
et al (2013) Effects of high‑density lipoprotein elevation with cholesteryl 
ester transfer protein inhibition on insulin secretion. Circ Res 113:167–175
 13. Abbasi A, Dallinga‑Thie GM, Dullaart RP (2015) Phospholipid transfer 
protein activity and incident type 2 diabetes mellitus. Clin Chim Acta 
439:38–41
 14. Barter PJ, Rye KA (2012) Cholesteryl ester transfer protein inhibition as a 
strategy to reduce cardiovascular risk. J Lipid Res 53:1755–1766
 15. Low H, Hoang A, Forbes J, Thomas M, Lyons JG, Nestel P et al (2012) 
Advanced glycation end‑products (AGEs) and functionality of reverse 
cholesterol transport in patients with type 2 diabetes and in mouse 
models. Diabetologia 55:2513–2521
 16. Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA et al 
(2009) In vitro simultaneous transfer of lipids to HDL in coronary artery 
disease and in statin treatment. Lipids 44:917–924
 17. Maranhao RC, Freitas FR (2014) HDL metabolism and atheroprotection: 
predictive value of lipid transfers. Adv Clin Chem 65:1–41
 18. Maranhao RC, Freitas FR, Strunz CM, Santos RD, Mansur AJ, Mansur AP 
et al (2012) Lipid transfers to HDL are predictors of precocious clinical 
coronary heart disease. Clin Chim Acta 413:502–505
 19. Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene 
AD et al (1995) The Medicine, Angioplasty or Surgery Study (MASS): a 
prospective, randomized trial of medical therapy, balloon angioplasty 
or bypass surgery for single proximal left anterior descending artery 
stenoses. J Am Coll Cardiol 26:1600–1605
 20. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concen‑
tration of low‑density lipoprotein cholesterol in plasma, without use of 
the preparative ultracentrifuge. Clin Chem 18:499–502
 21. Lima E, Maranhão RC (2004) Rapid, simple laser‑light scattering method 
for HDL particle size in whole plasma. Clin Chem 50:1086–1091
 22. Bragdon JH, Eder HA, Gould RG, Havel RJ (1956) Lipid nomenclature: rec‑
ommendations regarding the reporting of serum lipids and lipoproteins 
made by the Committee on Lipid and Lipoprotein Nomenclature of the 
American Society for the Study of Arteriosclerosis. Circ Res 4:129
 23. Marotta T, Russo BF, Ferrara LA (2010) Triglyceride‑to‑HDL‑cholesterol 
ratio and metabolic syndrome as contributors to cardiovascular risk in 
overweight patients. Obesity 18:1608–1613
Page 9 of 9Sprandel et al. Cardiovasc Diabetol  (2015) 14:107 
 24. Hermans MP, Ahn SA, Rousseau MF (2014) Novel unbiased equations 
to calculate triglyceride‑rich lipoprotein cholesterol from routine non‑
fasting lipids. Cardiovasc Diabetol 13:56
 25. Seviour PW, Teal TK, Richmond W, Elkeles RS (1988) Serum lipids, lipopro‑
teins and macrovascular disease in non‑insulin‑dependent diabetics: a 
possible new approach to prevention. Diabet Med 5:166–171
 26. Kahri J, Syvanne M, Taskinen MR (1994) Plasma cholesteryl ester transfer 
protein activity in non‑insulin‑dependent diabetic patients with and 
without coronary artery disease. Metabolism 43:1498–1502
 27. Frohlich J, Dobiasova M (2003) Fractional esterification rate of cholesterol 
and ratio of triglycerides to HDL‑cholesterol are powerful predictors of 
positive findings on coronary angiography. Clin Chem 49:1873–1880
 28. Ng DS (2012) The role of lecithin: cholesterol acyltransferase in the modu‑
lation of cardiometabolic risks—a clinical update and emerging insights 
from animal models. Biochim Biophys Acta 1821:654–659
 29. Savel J, Lafitte M, Pucheu Y, Pradeau V, Tabarin A, Couffinhal T (2012) Very 
low levels of HDL cholesterol and atherosclerosis, a variable relation‑
ship—a review of LCAT deficiency. Vasc Health Risk Manag 8:357–361
 30. Rousset X, Shamburek R, Vaisman B, Amar M, Remaley AT (2011) Lecithin 
cholesterol acyltransferase: an anti‑ or pro‑atherogenic factor? Curr 
Atheroscler Rep 13:249–256
 31. Couto RD, Dallan LA, Lisboa LA, Mesquita CH, Vinagre CG, Maranhao RC 
(2007) Deposition of free cholesterol in the blood vessels of patients with 
coronary artery disease: a possible novel mechanism for atherogenesis. 
Lipids 42:411–418
 32. Santos RD, Hueb W, Oliveira AA, Ramires JA, Maranhao RC (2003) Plasma 
kinetics of a cholesterol‑rich emulsion in subjects with or without coro‑
nary artery disease. J Lipid Res 44:464–469
 33. Khera AV, Cuchel M, de la Llera‑Moya M, Rodrigues A, Burke MF, Jafri K 
et al (2011) Cholesterol efflux capacity, high‑density lipoprotein function, 
and atherosclerosis. New Eng J Med 364:127–135
 34. Triolo M, Kwakernaak AJ, Perton FG, de Vries R, Dallinga‑Thie GM, Dullaart 
RP et al (2013) Low normal thyroid function enhances plasma cholesteryl 
ester transfer in type 2 diabetes mellitus. Atherosclerosis 228:466–471
 35. Dullaart RP, de Vries R, Dallinga‑Thie GM, van Tol A, Sluiter WJ (2007) 
Plasma cholesteryl ester transfer protein mass and phospholipid transfer 
protein activity are associated with leptin in type 2 diabetes mellitus. 
Biochim Biophys Acta 1771:113–118
 36. Inukai Y, Ito K, Hara K, Yamazaki A, Takebayashi K, Aso Y et al (2007) Serum 
cholesteryl ester transfer protein concentrations are associated with 
serum levels of total cholesterol, beta‑lipoprotein and apoproteins in 
patients with type 2 diabetes mellitus. Med Princ Pract. 16:367–372
 37. Morton RE (1988) Free cholesterol is a potent regulator of lipid transfer 
protein function. J Biol Chem 263:12235–12241
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
